Fundraising FoxTorl Bio
Culver City, US · 6 known investors
Find your way into Torl Bio
Sign up to see every warm intro you have to Torl Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Torl Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TORL BioTherapeutics develops antibody-drug conjugates (ADCs) targeting Claudin 6 (CLDN6) for the treatment of solid tumors such as ovarian, lung, endometrial, and testicular cancers. Its clinical-stage program centers on ixotatug vedotin, currently in a global Phase 2 study for platinum-resistant ovarian cancer.
Founders & leadership
Investors · 6
How we know: OCV Partners's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$254.3M disclosed across 2 of 3 rounds · 2023–2025
▶$158.3MraisedApr 2024 · 52 investors · PharmaceuticalsRule 506(b)
- Mark AllesExecutive Officer, Director
- Mark AttanasioDirector
- David LicataExecutive Officer, Director
- Neil O'BrienDirector
- Amit SinhaDirector
- Lynn SeelyDirector
- Dennis SlamonDirector
- Offering amount
- $158.3M
- Amount sold
- $158.3M
- First sale
- Apr 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Torl Bio do?
- TORL BioTherapeutics develops antibody-drug conjugates (ADCs) targeting Claudin 6 (CLDN6) for the treatment of solid tumors such as ovarian, lung, endometrial, and testicular cancers. Its clinical-stage program centers on ixotatug vedotin, currently in a global Phase 2 study for platinum-resistant ovarian cancer.
- Who are Torl Bio's investors?
- Torl Bio's investors include OCV Partners, RA Capital, Cowen Healthcare Investments, Goldman Sachs, Perceptive Xontogeny Venture, Vertex Ventures HC.
- How much funding has Torl Bio raised?
- Torl Bio has disclosed $254.3M raised across 2 of its 3 known rounds.
- Where is Torl Bio headquartered?
- Torl Bio is headquartered in Culver City, US.